Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Unusual Options Activity For February 12
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...